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Known chemoproteomic probes generally use warheads that tag a single type of amino acid or modified form thereof to 
identify cases in which its hyper-reactivity underpins function. Much important biochemistry derives from electron-poor 
enzyme cofactors, transient intermediates and chemically-labile regulatory modifications, but probes for such species are 
underdeveloped. Here, we have innovated a versatile class of chemoproteomic probes for this less charted hemisphere of 
the proteome by using hydrazine as the common chemical warhead. Its electron-rich nature allows it to react by both polar 
and radicaloid mechanisms and to target multiple, pharmacologically important functional classes of enzymes bearing 
diverse organic and inorganic cofactors. Probe attachment can be blocked by active-site-directed inhibitors, and elaboration 
of the warhead supports connection of a target to a lead compound. The capacity of substituted hydrazines to profile, 
discover and inhibit diverse cofactor-dependent enzymes enables cell and tissue imaging and makes this platform useful 
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MAIN 
Chemical biology probes for protein profiling have been used to discover enzymes, inhibitors and drugs1-3. Many of 
these probes are, by design, agnostic to molecular recognition by specific active sites but leverage chemically selective 
warheads that covalently couple to only one of the 20 amino acids4 or a modified form thereof5. This tagging of functionally 
hyper-reactive residues often identifies sites of catalysis in enzymes6. For such classical activity-based approaches7, 
covalent coupling to the reactive residue that defines an enzyme family or functional class can be used to read out (profile) 
that type of activity across the proteome, without prior knowledge of the individual substrates or transformations and in the 
absence of any biased molecular recognition. Because catalytic residues within an enzyme family are often readily predicted 
by genetics and bioinformatics, probes can be intentionally designed according to the known chemical selectivity of the 
warhead. In more recent extensions of this approach, ligand-based probes have been used to target hotspots of functionally 
diverse binding sites across the proteome8. Here, amino acid-selective warheads (for cysteine9, lysine10, aspartate11 or 
tyrosine12) or photoreactive handles13,14 have been applied to recognize and tag modestly activated amino acids in solvent-
accessible binding pockets, including active and allosteric sites of enzymes, receptors and other types of druggable proteins. 
These approaches enable i) discovery of protein activities or ligandability on the basis of enhanced reactivity with a specific 
probe and ii) subsequent identification of target-selective small molecules by chemical elaboration of the attacking warhead 
or by screening for potent inhibitors of attachment of the original, nondescript probe. 
Functional reactivity of the proteome extends beyond reactive amino acids, yet chemoproteomic platforms to 
discover, profile and modulate such functionality are underdeveloped. Cofactor-dependent enzymes, transient 
intermediates and other chemically labile protein modifications engage in catalytic and regulatory functions that are vital for 
virtually every cellular process, as they participate in challenging and diverse chemical transformations and sophisticated 
signal-transduction pathways that are conserved across biology15,16. A large fraction of enzyme cofactors are electron-
deficient in their resting or intermediate states. A hypothetical chemoproteomic platform to globally target cofactor-harboring 
enzyme active sites would require an electron-rich warhead that would be agnostic to both active site structure and 
functional group identity, recognizing only this general electron deficiency. A probe based on such a generalized warhead 
would have the capacity (i) to target all protein classes that utilize electron-deficient moieties for physiological function and 
(ii) to globally capture such species while operating in native biological systems across diverse physiological contexts.  
Hydrazine could potentially represent such a broad-spectrum covalent warhead for a chemoproteomic platform to 
capture cofactor-dependent enzymes. Its electron-rich nature makes it both nucleophilic and reducing, allowing for broad 
reactivity toward electron-deficient groups. In a previous study17, hydrazine was used as warhead for reverse-polarity (RP) 
activity-based protein profiling (ABPP). Initially expecting the warhead to act only as a nucleophile to target polar 
electrophiles such as carbonyl, ester and imine groups, we identified unexpected targets not known to harbor such 
electrophiles. Here, we show that the previously unexplained targeting of these proteins resulted from the reactivity of 
hydrazines also toward radicaloid oxidants. We show that this property confers unprecedented versality for generalized 
probing of both stable and transient electron deficient moieties in proteins. The hydrazine probes broadly capture enzymes 
across multiple different functional classes by distinct chemical mechanisms, but retain the active site targeting and 
dependence on functional state that have made conventional ABPP probes such powerful tools for inhibitor and drug 
discovery. By targeting reactive groups acquired post-translationally or transiently in the act of catalysis, our probes enable 
discovery of functionally relevant but not readily genetically predictable reactive moieties in enzymes. As such, they 




Global map of hydrazine-reactive proteome. Alkyl probe 1 and aryl probe 2 (Fig. 1a) were previously used to 
discover protein electrophiles17. However, we envisioned dual profiling platforms of both electrophilic and oxidizing 
functionality in the proteome, potentially operating as activity-based and mechanism-based inactivators (MBI) of known and 
unknown oxidizing centers in proteins18,19. We synthesized a “clickable” hydrazine probe, 3, which is chemically similar to 
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probes used in the previous work but more closely resembles the known drug phenelzine (alkylaryl hydrazine 4 in Fig. 1a). 
Phenelzine is the best studied hydrazine-bearing drug. It functions by irreversibly inhibiting monoamine oxidase (MAO)18,19, 
the neurotransmitter-metabolizing enzyme, by an O2-dependent radical mechanism that results in alkylation of the covalently 
bound flavin adenine dinucleotide (FAD) cofactor in the active site. It was an early therapy for depression and one of the 
first examples of oxidative activation of a hydrazine by an enzyme. Notably, it penetrates the brain, suggesting that, in 
general, substituted hydrazines might access even the most isolated tissue space.  
Gel-based proteomic profiles of 3 were generated by in situ treatment (0.5 h, 37 °C) of HEK293T and MDA-MB-231 
cells, followed by coupling of probe-captured proteins to an azide-rhodamine (Rh-N3) reporter tag using copper(I)-catalyzed  
azide-alkyne cycloaddition (CuAAC or “click” chemistry)20 and visualization by SDS–PAGE with in-gel fluorescence 
scanning1,17. Proteomic reactivity of 3 was both time- and dose-dependent, and labelling was blocked by pretreatment (15 
min, 37 °C) with 4 (Supplementary Fig. 1). To identify and quantify protein targets of probe 3 in situ, proteomic extracts from 
3-treated cells were fractionated, conjugated by CuACC chemistry to biotin-N3, enriched by adsorption to streptavidin resin 
and analyzed by mass spectrometry (MS)-based proteomics (Fig. 1b and Supplementary Fig. 2)1,17. To quantify high-
reactivity targets, proteomes from isotopically-labelled21 3-treated cells (1 mM, 0.5 h) were ratiometrically compared against 
proteomes obtained by cells subjected to two types of control treatments: to assess enrichment, cells were treated with 4 
under the same conditions as 3; to assess competition, cells were pretreated with 10-fold excess (10 mM, 15 min) of 4 
relative to 3. This latter experiment affords estimates from the purely ratiometric quantitation of both the relative abundance 
of a given target and how quantitively it is captured by the probe. Protein ratios were calculated from median peptide ratios 
from at least three unique quantified peptides per protein per experiment. Average competition ratios were plotted against 
average enrichment ratios (n ≥ 7 biological replicates; Supplementary Dataset 1) for proteins quantified in both types of 
experiments (Fig. 1c, Supplementary Dataset 1, and Supplementary Fig. 3). Proteins that were (i) substantially enriched by 
treatment with 3, coupling to biotin and absorption on streptavidin resin (ratio ≥ 5) and (ii) depleted by prior treatment with 
4 (ratio ≥ 3) in the upper right quadrant were taken to be high-reactivity targets (30 total proteins from the soluble and 
membrane fractions of the HEK293T and MDA-MB-231 cell lines). Representative peptide ratios from enrichment and 
competition experiments for four targets are shown in Fig. 1d. Meta-analysis of expanded 3-labelled proteins (enrichment 
ratio ≥ 5 or competition ratio ≥ 3) showed that, despite the facts that the competitor is an actual clinical drug and the probe 
is an analog of one, the majority of targets are not found in the DrugBank (61%, Fig. 1e). A large fraction of targets are 
known or predicted by genetics to have catalytic activity (Fig. 1f, left). Many members of this subset are known or predicted 
oxidoreductases (right). 
Capturing enzymes across multiple functional classes. As probe 3 (alkylaryl) is structurally-related to 1 (alkyl) 
and 2 (aryl)17, we aimed to understand how the target profiles compare and whether the hydrazine substituent confers 
selectivity. Profiles were aligned (Supplementary Dataset 2), and targets with enrichment ratios ≥ 5 or competition ratios ≥ 
3 for one or more of the probes in either cell line were compared in a Venn diagram (Fig. 1g). Alignment of targets according 
to known or predicted cofactor usage (e.g. flavin, heme) or post-translational modification generated an activity-based 
heatmap (Fig. 1h and Supplementary Table 1). All three probes showed preference for SCRN3 – an uncharacterized 
enzyme that previously provided the first example of a naturally occurring N-terminal glyoxylyl (Glox) electrophile. 1 and 2 
both targeted enzymes with functional electrophilic species such as pyruvoyl (Pyvl), formylglycyl (Fgly) or succinimide 
(Succ)17, whereas 2 and 3 targeted only partly overlapping sets of enzymes in other functional classes, including those 
defined by the use of oxidizing cofactors such as FAD, iron (Fe) or copper (Cu). 3 selectively targets MAOA and MAOB, 
consistent with its covalent capture of covalently-bound FAD according to the known mechanism of phenelzine (4)18.  
The data illuminate the potential for hydrazine to serve as general mechanism-based warhead for enzyme targets 
well beyond MAO. Notably, other flavoproteins with noncovalently-bound FAD cofactors (e.g. lysine-specific histone 
demethylase 1A (KDM1A) and ribosyldihydronicotinamide dehydrogenase [quinone] (NQO2)) are also highest-reactivity 
targets of 3, implying that it can directly covalently couple to the enzymes themselves in addition to the FAD cofactor. Iron(II)- 
and 2-oxoglutarate-dependent (Fe/2OG) enzymes – including fat mass and obesity-associated dioxygenase (FTO), the O2-
dependent RNA demethylase that is critical for an array of cellular processes and disease states, including CNS function22, 
obesity23 and cancer24 – were also identified as specific probe targets, with 2 being more selective than 3 toward these 
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enzymes. To the best of our knowledge, this represents the first report of the targeting of an Fe/2OG enzyme with a covalent 
inactivator.  
Activity-based probes for three unexpected classes. The broad reactivity of the hydrazine probes could 
represent either an asset or a liability: the question turns on whether their capture of the diverse enzyme targets remains 
active-site-directed and dependent on functional state, the two crucial traits that have made classical ABPP probes such 
useful tools in inhibitor and drug discovery. This issue was investigated by gel-based profiling of enzymes from four diverse 
structural and mechanistic classes: (i) covalently-bound FAD-dependent monoaminergic amine oxidases (MAOA, MAOB) 
as a control, (ii) noncovalent flavoenzymes (epigenetic eraser KDM1A and detoxifying quinone reductase NQO2), (iii) 
functionally uncharacterized SCRNs (SCRN1-3) and (iv) FTO. Overexpressed wild-type proteins from probe-treated 
HEK293T cells retained the hydrazine reactivity and probe preference observed by proteomics analysis of their endogenous 
forms (Fig. 2a-c). In all cases, labelling was abolished by substitution of active site residues that are essential for activity 
and/or productive cofactor binding. These observations confirm that capture by the probes requires the enzymes to be 
active (Fig. 2a-c)18,25-27.  
Our identification of SCRN2 as a probe-reactive target suggests, on the basis of its analogy to the previously 
characterized SCRN3, that it also reacts with the hydrazine warhead through a Cys-derived N-terminal Glox and/or Pyvl 
group. Probe labelling was abolished by replacement of cysteine 12, the residue predicted to support its hypothetical 
hydrolase activity. This residue also aligns with the Cys6 of SCRN3 (Fig. 2b) that is transformed to Glox. Probes deployed 
in the prior study17 could not differentiate between SCRN2 and SCRN3 isoforms, and only for SCRN3 was the distribution 
of N-terminally distinct forms determined. Here, SCRN2 ratios (Renrich/comp ≥ 20) were consistently higher than for SCRN3 
(Renrich/comp ≤ 4) in a given cell line, suggesting that probe 3 might be selective for isoform 2 (Fig. 1h and Supplementary 
Dataset 1). In gel-labelling profiles for overexpressed SCRN2 and SCRN3, probe 3 labelled both isoforms more intensely 
than probe 2 (Fig. 2b). By contrast, no hydrazine reactivity was observed for SCRN1, which has a serine rather than cysteine 
at the position that, in isoform 3 (and, as shown below, also isoform 2), becomes Glox. Replacement of the SCRN1 Ser with 
Cys did not result in acquisition of reactivity toward the probes, suggesting that additional factors are important in 
determining whether Glox is installed (Fig. 2b). The data suggest that 3 may be a valuable tool for investigating endogenous 
SCRN2/3 activity and that that even subtle modification to the probe can engender selectivity not only between functional 
enzyme classes but also between isoforms within the same class. 
Similarly, FTO is a selective target of 217 but not 3 (Fig. 1h and 2c), and its labelling was abolished by substitution 
of residues that coordinate the cofactor (His231, His307 and Asp233) or make key contacts with the 2OG cosubstrate 
(Arg361)28,29 (Fig. 2c). In addition, pretreating FTO-overexpressing HEK293T cells with the prolyl hydroxylase domain (PHD) 
inhibitor 1,4-DPCA (5), an iron chelator known for its anticancer30 and regenerative activities31, blocked probe labelling in a 
dose-dependent manner, suggesting that, in cells, the labelling event is both active-site-directed and dependent on the 
presence of the cofactor (Fig. 2d). Meclofenamate (6), a non-steroidal, anti-inflammatory (NSAID) drug known to inhibit 
FTO32, also blocked probe labelling, and the dependence of signal abrogation on inhibitor concentration was consistent with 
the IC50 for binding of the drug (Fig. 2e). Likewise, GSK2879552 (7), a cyclopropylamine-containing KDM1A inhibitor with 
anticancer activity, also blocked probe labelling with an IC50 that is comparable to the published Kiapp for its target33,34 (Fig. 
2f). Probe blocking by other covalent and noncovalent inhibitors is analyzed in Supplementary Fig. 4. The direct blockade 
of functional enzymes suggests a promising route for inhibitor screening in drug discovery.  
Mapping sites and mechanisms of covalent inactivation by substituted hydrazines in living cells. Phenelzine 
and related monoamine oxidase inhibitors (MAOIs) covalently target N5 of the FAD cofactor18. By the same mechanism, 
related small molecules inhibit other enzymes with noncovalent FAD cofactors (e.g. NQO235 and KDM1A36). Reaction of 3 
by an analogous mechanism (Fig.3a, upper) would not, in our experiments, lead to enrichment of an enzyme bearing a 
noncovalently bound flavin, because covalency with the protein is required for retention on the resin and detection by SDS-
PAGE. Nevertheless, formation of reactive radicals, first on the nitrogen of the hydrazine warhead and subsequently, by 
radical elimination of N2 on carbon (R• in Fig. 3a), could potentially result in covalent coupling directly to the protein in the 
vicinity of the active site (Fig.3a, lower). To understand the basis of the previously reported inhibition of KDM1A by 
phenelzine and our observation here that NQO2 is also targeted by the phenelzine-mimicking probe, we identified the small 
.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted June 18, 2020. . https://doi.org/10.1101/2020.06.17.154864doi: bioRxiv preprint 
 5
molecule and protein products of the labelling reactions. Following reaction of either 3 or 4 with reconstituted NQO2 
overexpressed in and purified from E. coli, FAD adducts were readily detected by LC-MS. The detected species had parent 
masses implying loss of the N2H4 fragment from the probe during the coupling reactions (Supplementary Fig. 5). To confirm 
that radical coupling with the protein can also occur and that this event explains targeting of the enzymes by the probes 
(Fig. 2a), we determined sites of labelling using a workflow adapted from the published study17 (isoTOP-ABPP6) to enrich 
and identify the probe-labelled protein fragment(s) as isotopically differentiated pairs of peptides (Fig. 3b and Supplementary 
Fig. 2). The predominant site that we identified for NQO2 labelling (Fig. 3c and Supplementary Fig. 6) is involved in cofactor 
binding37, and the parent mass determined for this peptide implies a net loss of N2H4 during coupling by the probe. Similarly, 
we resolved the predominant site in KDM1A (site 1) to two residues in the FAD-binding pocket that define the interface 
accommodating the dimethyl-isoalloxazine ring of the cofactor38 (Fig. 3d and Supplementary Fig. 7). A secondary site on 
the periphery of the active site was detected at much lower levels (Fig. 3d and Supplementary Fig. 8). For both NQO2 and 
KDM1A, the analytical data are consistent with MBI of the flavoenzymes by the hydrazine-based probes. Mass errors and 
statistics for all probe-labelled peptides of proteins discussed are summarized in Supplementary Tables 2 and 
3, respectively. 
To test the hypothesis that SCRN2 harbors a Cys-derived Glox that is captured by 3 to form a hydrazone (Fig. 4a), 
we applied the same method used for the flavoproteins above. Processed proteomes from 3-treated SCRN2-transfected 
HEK293T cells were analyzed by LC-MS/MS using an unbiased search strategy as described in Supplemental Methods to 
reveal a 3-Glox adduct at the position of Cys12 in the primary translation product (Fig. 4b and Supplementary Fig. 9). 
Consistent with the assignment of this peptide, its parent mass shifted the appropriate 2 Da when 3 was replaced with its 
15N-isotopologue (15N2-3) (inverted spectra in Fig. 4b and Supplementary Fig. 10). Importantly, daughter b ions but not y 
ions of the MS2 fragmentation spectra shifted also by 2 Da, confirming that both N-atoms of hydrazine were retained in the 
protein-probe adduct. As positive controls, we also characterized 3- and 15N2-3-captured Glox (Supplementary Fig. 11 and 
12) and Pyvl (Supplementary Fig. 13 and 14) peptides from SCRN3; they also demonstrated retention of the N2 unit. It is 
noteworthy that, unlike for the case of SCRN3, no pyruvoyl-appended SCRN2 (Pyvl-SCRN2) could be detected, suggesting 
that the N-terminus is more completely processed in isoform 2 and lending weight to the prior suggestion that Glox is the 
functional form of SCRN2/3. More broadly, the use of 15N-isotopologues to demonstrate whether the nitrogen atoms of the 
hydrazine are or are not retained during probe capture allows for immediate distinction of electrophilic versus radicaloid 
mechanisms of hydrazine inactivation, as applied below (Supplementary Fig. 15).  
We observed that only probe 2 (not 3) targeted FTO (Fig. 1h and 2c). This probe selectivity contrasts with the 
behavior of the Glox- and FAD-harboring enzymes and suggests a distinct mechanism of probe capture of the Fe/2OG 
enzymes. It also establishes that relatively subtle details of structure can tune probes to be either more promiscuous or 
more selective with respect to different functional classes. Here, iron-hydrazine chelation may be an initial step, as 
hydrazide- and hydroxylamine-containing compounds have been shown to inhibit FTO39 by binding iron. However, to our 
knowledge, hydrazine reactivity leading to covalent enzyme modification has not yet been reported for a member of the 
Fe/2OG enzyme class. To define the mode of probe labelling, we used N-isotopologues of 2 to capture FTO from 
overexpressing HEK293T cells. SCRN3 was targeted as a control (Supplementary Fig. 16-19). Peptide pairs from both 
datasets were filtered according to retention time, parent mass, MS1 intensity and sample specificity (Supplementary 
Dataset 3). This analysis yielded only 15N-insensitive pairs (three) from the FTO dataset, suggesting a loss of at least the 
terminal nitrogen atom from the probe during coupling to the Fe/2OG enzyme (Supplementary Fig. 15 and Supplementary 
Fig. 20). The experimental MS2 spectra of the most abundant pair were searched against theoretical MS2 spectra for all 
possible peptide assignments for FTO. Using this approach, the predominant site of probe capture could be definitively 
assigned to His231 (Fig. 5a-b and Supplementary Fig. 21-22), one of the three cofactor ligands28,29. The mass of the peptide 
and corresponding 15N insensitivity are consistent with enzyme activation of the probe in a radical manifold that results in 
arylation of the His-coordinated side chain with loss of N2 (Fig. 5c). As can be seen from the crystal structure of FTO with 
bound nucleic acid substrate, His arylation should almost certainly disrupt binding of the substrate, 2OG cosubstrate, and/or 
iron cofactor (Fig. 5d). The data show that hydrazines define a new class of mechanism-based inactivator for this Fe/2OG 
enzyme. In addition to FTO, we identified 14 other Fe/2OG enzymes belonging to separate sequence clades and functional 
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classes as high-reactivity probe targets (Fig. 1h and Supplementary Fig. 23), suggesting that the coupling mechanism is 
likely to be general. 
Spatial resolution across diverse physiological contexts. We sought to assess whether hydrazine probes could 
also serve as versatile tools for activity-based imaging. For live cell imaging, 3-treated HEK293T cells were visualized with 
and without in-cell fluorophore conjugation (CuAAC of Rh-N3), and with and without pretreatment with drug 4 under the 
same conditions described for the gel- and MS-based proteome profiling experiments (Fig. 6a). Labelling by 3 (lower left) 
was dependent on CuAAC (upper right), and 4 (lower right) diminished the mean fluorescence intensity by 48%, consistent 
with the average extent of competition seen in probe labelling profiles of soluble and membrane proteomes (45%) (Fig. 6a 
upper left and Supplementary Fig. 1). Fixed tissues from clinically relevant samples have altered metabolic activities for 
many enzyme classes. To evaluate the fraction of enzyme activities that can be captured in this context by our platform, the 
hydrazine-sensitive proteome preserved in formalin-fixed paraffin-embedded (FFPE) mouse lung tissue was investigated. 
Labelling by 3 (333 µM, 1 h) was strongly suppressed by a 10-fold excess of 4 (3.3 mM, 1 h), which diminished the composite 
fluorescence intensity by 84% (Fig. 6b). These results demonstrate that probe labelling can be effectively performed in both 
live cells and tissues. It should be possible to further elaborate probe molecules to develop more selective compounds that 
enable spatially resolved activity maps for existing histological samples and chemical druggability maps for existing genetics 
and epigenetics. With these complementary capabilities, the platform can be expected to enable discovery of new targets 




Classical ABPP represented a creative fusion of established and emerging technologies. Amino acid-selective 
chemical modifiers, developed decades before, were repurposed to identify proteins with a specific type of residue serving 
a functional role. Whereas labelling every instance of a specific amino acid (e.g. all serines, cysteines etc.) in a raw, complex 
proteome would not obviously, a priori, be a profitable endeavor, the emerging power of MSn proteomics to resolve nmol 
levels of thousands, if not tens of thousands, of proteins in a complex mixture enabled individual targets to be identified7. 
Moreover, it rested on the tenet that proteins having a specific amino acid to engage covalently as part of its function often 
tune that residue to be hyperreactive with respect to purely structural amino acids of the same type. Thus, limited treatments 
with sub-saturating probe were used to selectively identify the functional residues of the type being targeted. Once a 
particular modifier of an active site residue is identified, other molecules that bind selectively to that site can be identified by 
virtue of their ability to prevent probe attachment1. Importantly, because the chemical functionalities being targeted invariably 
arose from the common amino acids, selectivity for a single type was crucial to avoid excessive complexity and enable 
sorting of the many targets in a complex mixture. 
Recognizing the historical bias for genetically encoded nucleophilic groups, we previously reversed the polarity of 
ABPP by using a nucleophilic probe, with the intent of discovering electrophiles17. Such species are present in proteins 
primarily in the forms of regulatory post-translational modifications and (in)organic enzyme cofactors. In this other less 
explored hemisphere of the proteome, reactive functionality is comparatively rare and almost uniformly associated with 
chemical function. In this case, use of a single probe warhead to capture many or all electrophilic or electron-deficient 
chemical functionality in the proteome without compromising the ability to resolve the individual targets by MSn approaches 
seemed feasible. Our data demonstrate that, by virtue of their nucleophilicity and capacity to form carbon radicals that can 
attach promiscuously to side chains and backbones of proteins, organohydrazines provide such a versatile, if not completely 
general, warhead to identify electron deficient functional groups in proteins without prior knowledge of their identity or even 
their presence. The hydrazine probes deployed herein are mechanism-based, active-site-directed and blocked by inhibitors 
that occupy active sites. As such, they can be used in the same way that amino acid-selective modifiers have been applied 
so successfully. Further, their capacity to access even the most isolated tissue space of the brain (e.g., in the antidepressant, 
phenelzine)18,40 will make them useful for in vivo imaging and assessment of target engagement or tissue distribution. 
A central tenant of the ABPP approach is the ability to measure biomolecular activity, independent of transcription 
and translation levels, to uncover post-transcriptional and metabolic modes of regulation7. Methods to globally and directly 
measure active states of enzymes are invaluable for understanding how their activities are (dys)regulated, how they can be 
.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted June 18, 2020. . https://doi.org/10.1101/2020.06.17.154864doi: bioRxiv preprint 
 7
pharmacologically modulated, and in which physiological context doing so might be therapeutically relevant. For Fe/2OG 
enzymes, for example, activity is impacted not only by gene and transcript levels but also by the availability of oxygen, iron 
and energetic metabolites, as these enzymes are cellular sensors that control the fundamental response pathways in which 
their cofactors/cosubstrates participate (e.g. hypoxia, metal trafficking and 2OG metabolism)41. Similarly, flavoenzyme 
activation is determined not only by the availability of vitamin precursors and integrity of biosynthetic enzymes required for 
cofactor generation but also by its trafficking and compartmentalization, which must also be precisely titrated to mirror 
dynamic levels of myriad client apoenzymes with diverse and essential functions42. For these reasons, hydrazine-based 




Methods section is provided in the Supplementary Information with details available. 
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Fig. 1. Hydrazine pharmacophores broadly capture enzymes across multiple functional classes in human cells. a, 
Structures of hydrazine probes (alkyl probe 1, aryl probe 2 and alkylaryl probe 3 with corresponding isotopologues 15N-2 
and 15N2-3) and CNS drug phenelzine 4 (non-clickable analogue of 3). Green designates hydrazine warheads. b, Schematic 
for MS2-based quantitative proteomics experiments (enrichment and competition) using stable isotopic labelling by amino 
acids in cell culture (SILAC)21. Isotopically heavy and light cells, proteomes, and peptides are depicted in blue and red, 
respectively. c, Quadrant plot of average competition versus enrichment protein ratios for probe 3 from quantitative 
proteomic analysis of the soluble proteome of HEK293T cells. Highest-reactivity targets (upper right quadrant) found in both 
experiments and labelled by probe 3 are highlighted in red. d, Extracted MS1 chromatograms and corresponding heavy/light 
ratios (enrichment and competition) for representative tryptic peptides of endogenous forms of highest-reactivity targets. e, 
Fraction of 3-labelled proteins from HEK293T and MDA-MB-231 cells found in DrugBank and f, their known or predicted 
functional classes. g, Venn diagram of shared and unique protein targets of probes 1-3 from both cell lines. h, Heatmap 
showing relative protein enrichment and competition indices for targets known or predicted to harbor electron-deficient 
moieties. Targets are grouped on the basis of type of electron-deficient group, electrophilic (yellow) or oxidizing (red), and 
electron-deficient cofactor class. Structures for three diverse classes (Glox, FAD and Fe/2OG) are shown.  
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Fig. 2. Covalent labelling is dependent on functional state and blocked by active-site-directed inhibitors. Probe 
labelling (upper) and expression profiles (lower) for probe-treated cells expressing the indicated protein target or inactive 
variant thereof. Transfection with the appropriate empty expression vector (‘mock’) is used as a control. Molecular weights 
are indicated. a, 3-labelling of wild-type MAOA, KDM1A and NQO2 flavoenzymes but not catalytically inactive variants. b, 
Sequence alignment of SCRN proproteins (upper), cleavage site, and Cys residue (red) predicted to be catalytic, but shown 
in SCRN3 to be post-translationally converted to Glox. 2- vs. 3-labelling (lower) profiles of SCRN1-3 compared to indicated 
variants. c, 2- vs. 3-labelling of wild-type FTO but not catalytically inactive variants. Dose-dependent inhibition of FTO-
labeling by 2 with d, iron chelator drug, 1,4-DPCA (5) and e, meclofenamate (6), a cyclooxygenase-2 (COX2) inhibitor also 
known to inhibit FTO. f, Dose-dependent inhibition of KDM1A-labelling by 3 with its covalent inhibitor GSK2879552 (7). 
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Fig. 3. Covalent probes for noncovalent flavin enzymes. Identification of sites of probe labelling in NQO2 and KDM1A. 
a, Schematic for oxidative activation of hydrazine probes and subsequent coupling of resultant carbon-centered radical to 
FAD (red) and active site (grey). b, Condensed isoTOP-ABPP workflow to identify 3-labelled peptides from treated cells 
overexpressing each flavoprotein target. c, Probe labelling site mapped onto the crystal structure of NQO2 bound to FAD 
(yellow). The identity of the probe 3-labelled peptide (aa 184-201) and site are shown in green and purple, respectively 
(left). Extracted MS1 ion chromatograms of co-eluting heavy- and light-tagged peptides are shown in blue and red, 
respectively. The peptide modified in human NQO2 (PDB: IQR2) is highlighted. d, Probe labelling sites mapped onto the 
crystal structure of KDM1A bound to FAD (yellow). The identities of 3-labelled peptides (aa 759-795 and 551-568) and sites 
are shown in green and purple, respectively (left). Extracted ion chromatograms of co-eluting heavy- and light-tagged 
peptides (blue and red, respectively) are shown in the middle. Peptides modified in human KDM1A (PDB: 2HKO) are 
highlighted. 
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Fig. 4. De novo discovery of Glox in SCRN2. a, Schematic for formation of Glox in SCRNs and subsequent capture by 
hydrazine probes. b, Monoisotopic m/z values of co-eluting heavy- and light-tagged peptides (blue and red, respectively) 
for the 3-labelled Glox12-Lys28 SCRN2 peptide (upper left), extracted triply-charged MS1 ion chromatograms (lower left) 
and corresponding isotopic envelopes (right) shift the appropriate 2 Da (Δm/z 0.6647) when 3 is substituted with 15N2-3 
(inverted y-axis).  
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Fig. 5. Discovery of a mechanism-based inactivator of FTO and other Fe/2OG enzymes. a, MS1 peptide (aa 226-239) 
pairs and corresponding isotopic envelopes from FTO-transfected cells treated with 2 versus 15N-2. Extracted ion 
chromatograms using monoisotopic m/z values of co-eluting heavy- and light-tagged peptides (blue and red, respectively) 
are shown on the lower left. b, Comparison of high-resolution MS2 spectra generated from light- versus heavy-tagged 
parent ions. c, Schematic for enzyme activation of probe 2 in a radical manifold, resulting in arylation of the active site His 
side chain that coordinates to the iron center. The hydrazine warhead, 2OG and iron are shown in green, blue and brown, 
respectively. d, Probe labelling site mapped onto FTO crystal structure. The identity of the probe 2-labelled peptide (aa 226-
239) and site (H231) are shown in green and purple, respectively (left). Modified peptide is highlighted in human FTO (PDB: 
3LFM) with iron (brown), 2OG (yellow), and 3-methylthymine (gray) in the active site.  
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Fig. 6. Imaging probe-sensitive activities in cells and tissues. a, Image-based analysis compared to gel-based analysis 
of (upper left) subcellular localization of probe reactivity in HEK293T cells. 3-labelling in the absence (upper right) and 
presence (bottom left) of CuAAC and in competition with drug 4 (bottom right). Rhodamine is conjugated to the probe by 
CuAAC (magenta). Nuclei and membranes were stained with DAPI (blue) and WGA (green), respectively. Mean rhodamine 
labelling intensity was quantified using ImageJ (n = 3 per group), and group differences were evaluated by ANOVA followed 
by Bonferroni Post-hoc analysis (scale bar = 10 µm; * p < 0.05, *** p < 0.001). b, Image-based analysis of formalin-fixed 
paraffin-embedded (FFPE) mouse lung tissue labelled with probe 3 (magenta) and counterstained for acetylated tubulin 
(ac-Tub, green) and the nuclei with DAPI (blue) (upper). A ten-fold excess of competing drug 4 reduced probe labelling by 
84% (scale bar = 50 µm; p-value = 3.375 x 10-8, Student’s t-test) (lower). 
 
  
.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a




1 Niphakis, M. J. & Cravatt, B. F. Enzyme inhibitor discovery by activity-based protein profiling. Annu Rev Biochem 
83, 341-377, doi:10.1146/annurev-biochem-060713-035708 (2014). 
2 Jones, L. H. & Neubert, H. Clinical chemoproteomics-opportunities and obstacles. Sci Transl Med 9, 
doi:10.1126/scitranslmed.aaf7951 (2017). 
3 Drewes, G. & Knapp, S. Chemoproteomics and chemical probes for target discovery. Trends Biotechnol 36, 
1275-1286, doi:10.1016/j.tibtech.2018.06.008 (2018). 
4 Tamura, T. & Hamachi, I. Chemistry for covalent modification of endogenous/native proteins: from test tubes to 
complex biological systems. J Am Chem Soc 141, 2782-2799, doi:10.1021/jacs.8b11747 (2019). 
5 Shi, Y. & Carroll, K. S. Activity-based sensing for site-specific proteomic analysis of cysteine oxidation. Acc Chem 
Res 53, 20-31, doi:10.1021/acs.accounts.9b00562 (2020). 
6 Weerapana, E. et al. Quantitative reactivity profiling predicts functional cysteines in proteomes. Nature 468, 790-
795, doi:10.1038/nature09472 (2010). 
7 Cravatt, B. F., Wright, A. T. & Kozarich, J. W. Activity-based protein profiling: from enzyme chemistry to proteomic 
chemistry. Annu Rev Biochem 77, 383-414, doi:10.1146/annurev.biochem.75.101304.124125 (2008). 
8 Roberts, A. M., Ward, C. C. & Nomura, D. K. Activity-based protein profiling for mapping and pharmacologically 
interrogating proteome-wide ligandable hotspots. Curr Opin Biotechnol 43, 25-33, doi:10.1016/j.copbio.2016.08.003 
(2017). 
9 Backus, K. M. et al. Proteome-wide covalent ligand discovery in native biological systems. Nature 534, 570-574, 
doi:10.1038/nature18002 (2016). 
10 Hacker, S. M. et al. Global profiling of lysine reactivity and ligandability in the human proteome. Nat Chem 9, 
1181-1190, doi:10.1038/nchem.2826 (2017). 
11 Bach, K., Beerkens, B. L. H., Zanon, P. R. A. & Hacker, S. M. Light-activatable, 2,5-disubstituted tetrazoles for the 
proteome-wide profiling of aspartates and glutamates in living bacteria. ACS Cent Sci 6, 546-554, 
doi:10.1021/acscentsci.9b01268 (2020). 
12 Hahm, H. S. et al. Global targeting of functional tyrosines using sulfur-triazole exchange chemistry. Nat Chem Biol 
16, 150-159, doi:10.1038/s41589-019-0404-5 (2020). 
13 Niphakis, M. J. et al. A global map of lipid-binding proteins and their ligandability in cells. Cell 161, 1668-1680, 
doi:10.1016/j.cell.2015.05.045 (2015). 
14 Gao, J., Mfuh, A., Amako, Y. & Woo, C. M. Small molecule interactome mapping by photoaffinity labeling reveals 
binding site hotspots for the NSAIDs. J Am Chem Soc 140, 4259-4268, doi:10.1021/jacs.7b11639 (2018). 
15 Silverman, R. B. Organic chemistry of enzyme-catalyzed reactions.  (Academic Press, Cambridge, 2002). 
16 Walsh, C. T. Posttranslational modification of proteins: expanding nature's inventory.  (Roberts and Company 
Publishers, Greenwood Village, 2006). 
17 Matthews, M. L. et al. Chemoproteomic profiling and discovery of protein electrophiles in human cells. Nat Chem 
9, 234-243, doi:10.1038/nchem.2645 (2017). 
18 Binda, C. et al. Structural and mechanistic studies of arylalkylhydrazine inhibition of human monoamine oxidases 
A and B. Biochemistry 47, 5616-5625, doi:10.1021/bi8002814 (2008). 
19 Polasek, T. M. et al. An evaluation of potential mechanism-based inactivation of human drug metabolizing 
cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol 61, 570-584, 
doi:10.1111/j.1365-2125.2006.02627.x (2006). 
20 Rostovtsev, V. V., Green, L. G., Fokin, V. V. & Sharpless, K. B. A stepwise huisgen cycloaddition process: 
copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. Angew Chem Int Ed Engl 41, 2596-2599, 
doi:10.1002/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4 (2002). 
21 Ong, S. E. et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach 
to expression proteomics. Mol Cell Proteomics 1, 376-386, doi:10.1074/mcp.m200025-mcp200 (2002). 
22 Hess, M. E. et al. The fat mass and obesity associated gene (Fto) regulates activity of the dopaminergic midbrain 
circuitry. Nat Neurosci 16, 1042-1048, doi:10.1038/nn.3449 (2013). 
23 Claussnitzer, M. et al. FTO obesity variant circuitry and adipocyte browning in humans. N Engl J Med 373, 895-
907, doi:10.1056/NEJMoa1502214 (2015). 
24 Huang, Y. et al. Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia. Cancer Cell 
35, 677-691 e610, doi:10.1016/j.ccell.2019.03.006 (2019). 
25 Wu, H. F., Chen, K. & Shih, J. C. Site-directed mutagenesis of monoamine oxidase A and B: role of cysteines. 
Mol Pharmacol 43, 888-893 (1993). 
.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted June 18, 2020. . https://doi.org/10.1101/2020.06.17.154864doi: bioRxiv preprint 
 15
26 Karasulu, B., Patil, M. & Thiel, W. Amine oxidation mediated by lysine-specific demethylase 1: quantum 
mechanics/molecular mechanics insights into mechanism and role of lysine 661. J Am Chem Soc 135, 13400-13413, 
doi:10.1021/ja403582u (2013). 
27 Xu, J., Patrick, B. A. & Jaiswal, A. K. NRH:quinone oxidoreductase 2 (NQO2) protein competes with the 20 S 
proteasome to stabilize transcription factor CCAAT enhancer-binding protein alpha (C/EBPalpha), leading to protection 
against gamma radiation-induced myeloproliferative disease. J Biol Chem 288, 34799-34808, 
doi:10.1074/jbc.M113.495580 (2013). 
28 Han, Z. et al. Crystal structure of the FTO protein reveals basis for its substrate specificity. Nature 464, 1205-
1209, doi:10.1038/nature08921 (2010). 
29 Jia, G. et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem 
Biol 7, 885-887, doi:10.1038/nchembio.687 (2011). 
30 Xiong, G., Deng, L., Zhu, J., Rychahou, P. G. & Xu, R. Prolyl-4-hydroxylase alpha subunit 2 promotes breast 
cancer progression and metastasis by regulating collagen deposition. BMC Cancer 14, 1, doi:10.1186/1471-2407-14-1 
(2014). 
31 Zhang, Y. et al. Drug-induced regeneration in adult mice. Sci Transl Med 7, 290ra292, 
doi:10.1126/scitranslmed.3010228 (2015). 
32 Huang, Y. et al. Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5. Nucleic Acids 
Res 43, 373-384, doi:10.1093/nar/gku1276 (2015). 
33 Mohammad, H. P. et al. A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC. 
Cancer Cell 28, 57-69, doi:10.1016/j.ccell.2015.06.002 (2015). 
34 Tan, A. H. Y. et al. Lysine-specific histone demethylase 1A regulates macrophage polarization and checkpoint 
molecules in the tumor microenvironment of triple-negative breast cancer. Front Immunol 10, 1351, 
doi:10.3389/fimmu.2019.01351 (2019). 
35 Yan, C. et al. Indolequinone inhibitors of NRH:quinone oxidoreductase 2. Characterization of the mechanism of 
inhibition in both cell-free and cellular systems. Biochemistry 50, 6678-6688, doi:10.1021/bi2002967 (2011). 
36 Culhane, J. C., Wang, D., Yen, P. M. & Cole, P. A. Comparative analysis of small molecules and histone 
substrate analogues as LSD1 lysine demethylase inhibitors. J Am Chem Soc 132, 3164-3176, doi:10.1021/ja909996p 
(2010). 
37 Foster, C. E., Bianchet, M. A., Talalay, P., Zhao, Q. & Amzel, L. M. Crystal structure of human quinone reductase 
type 2, a metalloflavoprotein. Biochemistry 38, 9881-9886, doi:10.1021/bi990799v (1999). 
38 Chen, Y. et al. Crystal structure of human histone lysine-specific demethylase 1 (LSD1). Proc Natl Acad Sci U S A 
103, 13956-13961, doi:10.1073/pnas.0606381103 (2006). 
39 Toh, J. D. W. et al. A strategy based on nucleotide specificity leads to a subfamily-selective and cell-active 
inhibitor of N(6)-methyladenosine demethylase FTO. Chem Sci 6, 112-122, doi:10.1039/c4sc02554g (2015). 
40 Edmondson, D. E., Binda, C. & Mattevi, A. Structural insights into the mechanism of amine oxidation by 
monoamine oxidases A and B. Arch Biochem Biophys 464, 269-276, doi:10.1016/j.abb.2007.05.006 (2007). 
41 Hausinger RP, S. C. G. C. 2-Oxoglutarate-dependent oxygenases.  (Royal Society of Chemistry, Cambridge, 
2015). 
42 Lienhart, W. D., Gudipati, V. & Macheroux, P. The human flavoproteome. Arch Biochem Biophys 535, 150-162, 
doi:10.1016/j.abb.2013.02.015 (2013). 
 
.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted June 18, 2020. . https://doi.org/10.1101/2020.06.17.154864doi: bioRxiv preprint 
